Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction and clinical decision making

T Lion - Blood, The Journal of the American Society of …, 1999 - ashpublications.org
In the May 1, 1999 issue of Blood, Faderl et al1 discuss the possible clinical role of
polymerase chain reaction (PCR) analysis in the surveillance of residual disease in patients …
被引用次数：18 相关文章

[引用][C] Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction and clinical decision making

T LION - Blood, 1999 - cir.nii.ac.jp
Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase
chain reaction and clinical decision making | CiNii Research CiNii 国立情報学研究所 学術情報 …

[引用][C] Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction and clinical decision making.

T Lion - Blood, 1999 - europepmc.org
Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase
chain reaction and clinical decision making. - Abstract - Europe PMC Sign in | Create an …

[引用][C] Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction and clinical decision making

T Lion - Blood, 1999 - pubmed.ncbi.nlm.nih.gov

[引用][C] Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction and clinical decision making [7](multiple letters)

T Lion, S Faderl, M Talpaz, HM Kantarjian… - …, 1999 - mdanderson.elsevierpure.com
Monitoring of residual disease in chronic myelogenous leukemia by quantitative
polymerase chain reaction and clinical decision making [7] (multiple letters) — MD …